WO2004037180A3 - Compositions that treat or inhibit pathological conditions associated with inflammatory response - Google Patents

Compositions that treat or inhibit pathological conditions associated with inflammatory response Download PDF

Info

Publication number
WO2004037180A3
WO2004037180A3 PCT/US2003/033362 US0333362W WO2004037180A3 WO 2004037180 A3 WO2004037180 A3 WO 2004037180A3 US 0333362 W US0333362 W US 0333362W WO 2004037180 A3 WO2004037180 A3 WO 2004037180A3
Authority
WO
WIPO (PCT)
Prior art keywords
inflammatory response
inhibit
compositions
treat
conditions associated
Prior art date
Application number
PCT/US2003/033362
Other languages
French (fr)
Other versions
WO2004037180A2 (en
Inventor
Matthew L Tripp
John G Babish
Jeffrey S Bland
Gary Darland
Robert Lerman
Daniel O Lukaczer
Deann J Liska
Terrence Howell
Original Assignee
Metaproteomics Llc
Matthew L Tripp
John G Babish
Jeffrey S Bland
Gary Darland
Robert Lerman
Daniel O Lukaczer
Deann J Liska
Terrence Howell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/464,834 external-priority patent/US20040115290A1/en
Priority claimed from US10/464,410 external-priority patent/US8142819B2/en
Application filed by Metaproteomics Llc, Matthew L Tripp, John G Babish, Jeffrey S Bland, Gary Darland, Robert Lerman, Daniel O Lukaczer, Deann J Liska, Terrence Howell filed Critical Metaproteomics Llc
Priority to EP03777751A priority Critical patent/EP1558271A4/en
Priority to NZ539642A priority patent/NZ539642A/en
Priority to CA2503196A priority patent/CA2503196C/en
Priority to AU2003286549A priority patent/AU2003286549B2/en
Priority to MXPA05004288A priority patent/MXPA05004288A/en
Priority to US10/532,388 priority patent/US8486457B2/en
Priority to JP2005501640A priority patent/JP2006508182A/en
Publication of WO2004037180A2 publication Critical patent/WO2004037180A2/en
Publication of WO2004037180A3 publication Critical patent/WO2004037180A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
PCT/US2003/033362 2002-10-21 2003-10-20 Compositions that treat or inhibit pathological conditions associated with inflammatory response WO2004037180A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP03777751A EP1558271A4 (en) 2002-10-21 2003-10-20 Compositions that treat or inhibit pathological conditions associated with inflammatory response
NZ539642A NZ539642A (en) 2002-10-21 2003-10-20 Compositions containing extracts from hops in combination with a second component for treating inflammatory response
CA2503196A CA2503196C (en) 2002-10-21 2003-10-20 Compositions that treat or inhibit pathological conditions associated with inflammatory response
AU2003286549A AU2003286549B2 (en) 2002-10-21 2003-10-20 Compositions that treat or inhibit pathological conditions associated with inflammatory response
MXPA05004288A MXPA05004288A (en) 2002-10-21 2003-10-20 Compositions that treat or inhibit pathological conditions associated with inflammatory response.
US10/532,388 US8486457B2 (en) 2002-10-21 2003-10-20 Compositions that treat or inhibit pathological conditions associated with inflammatory response
JP2005501640A JP2006508182A (en) 2002-10-21 2003-10-20 A composition for treating or inhibiting a pathological condition associated with an inflammatory response.

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US42038302P 2002-10-21 2002-10-21
US60/420,383 2002-10-21
US45023703P 2003-02-25 2003-02-25
US60/450,237 2003-02-25
US40029303A 2003-03-26 2003-03-26
US40128303A 2003-03-26 2003-03-26
US10/401,283 2003-03-26
US10/400,293 2003-03-26
US10/464,834 US20040115290A1 (en) 2001-06-20 2003-06-18 Modulation of inflammation by hops fractions and derivatives
US10/464,410 2003-06-18
US10/464,834 2003-06-18
US10/464,410 US8142819B2 (en) 2002-10-21 2003-06-18 Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response

Publications (2)

Publication Number Publication Date
WO2004037180A2 WO2004037180A2 (en) 2004-05-06
WO2004037180A3 true WO2004037180A3 (en) 2004-09-30

Family

ID=32180835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/033362 WO2004037180A2 (en) 2002-10-21 2003-10-20 Compositions that treat or inhibit pathological conditions associated with inflammatory response

Country Status (9)

Country Link
US (1) US8486457B2 (en)
EP (1) EP1558271A4 (en)
JP (1) JP2006508182A (en)
KR (1) KR20050071605A (en)
AU (1) AU2003286549B2 (en)
CA (1) CA2503196C (en)
MX (1) MXPA05004288A (en)
NZ (1) NZ539642A (en)
WO (1) WO2004037180A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8241674B2 (en) 2007-05-11 2012-08-14 Metaproteomics, Llc Methods and compositions for heavy metal detoxification
US8846115B2 (en) 2001-11-13 2014-09-30 Metaproteomics, Inc. Anti-inflammatory cyclooxygenase inhibitors
CN112794872B (en) * 2021-04-02 2022-07-15 湖南德诺贝莱健康产业有限公司 Method for extracting luteolin-3' -glucuronide from rosemary

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115290A1 (en) * 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US8168234B2 (en) * 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7901713B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US7815944B2 (en) * 2001-06-20 2010-10-19 Metaproteomics, Llc Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment of prevention of gastric toxicity
US8142819B2 (en) * 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US7901714B2 (en) * 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
MXPA05004288A (en) 2002-10-21 2005-08-02 Metaproteomics Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response.
EP1626731B1 (en) 2003-05-22 2009-01-21 Metaproteomics, LLC Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US20050192356A1 (en) * 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US7914831B2 (en) * 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
JP4321769B2 (en) * 2004-04-13 2009-08-26 Towa Corporation 株式会社 Composition for antihistamine, composition for prevention and treatment of allergic rhinitis, composition for prevention and treatment of hay fever and composition for treatment of urticaria
AU2005304317A1 (en) * 2004-11-13 2006-05-18 Metaproteomics, Llc Compositions exhibiting inhibition of cyclooxygenase-2
US20080248131A1 (en) * 2005-08-09 2008-10-09 Metaproteomics, Llc Protein Kinase Modulation by Hops and Acacia Products
AU2012204133B2 (en) * 2005-08-09 2013-09-19 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
JP2009518439A (en) * 2005-12-09 2009-05-07 メタプロテオミクス,エルエルシー Protein kinase regulation by hops and acacia products
EP1968559A4 (en) * 2005-12-09 2013-08-07 Metaproteomics Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
JP5066706B2 (en) * 2006-02-28 2012-11-07 国立大学法人徳島大学 Screening method for anti-obesity agents
JP2009541326A (en) * 2006-06-20 2009-11-26 メタプロテオミクス, エルエルシー Beta acid-based protein kinase-regulated cancer therapy
US20080051466A1 (en) * 2006-06-20 2008-02-28 Metaproteomics, Llc Isoalpha acid based protein kinase modulation cancer treatment
JPWO2008026473A1 (en) 2006-08-31 2010-01-21 アサヒビール株式会社 Method for producing hop preparation, hop preparation, anti-inflammatory agent, food and drink, and oral product
KR20080025900A (en) * 2006-09-19 2008-03-24 (주) 서울바이오메드 A composition and a method for treatment of conjunctivitis comprising glucosamine and derivatives thereof
KR100893162B1 (en) * 2007-02-21 2009-04-17 바이오스펙트럼 주식회사 Agents for Improving Skin Wrinkles Comprising Carvacrol as an Active Ingredient
MX2009010049A (en) * 2007-03-19 2010-03-04 Metaproteomics Llc Methods and compositions for promoting bone and joint health.
CA2708613A1 (en) * 2007-12-10 2009-06-18 Metaproteomics, Llc Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith
JP2011516492A (en) * 2008-04-02 2011-05-26 メタプロテオミクス, エルエルシー Attenuation of endothelial inflammation and endothelium-monocyte interaction by substituted 1,3-cyclopentadione
KR100919898B1 (en) * 2008-07-24 2009-09-30 바이오스펙트럼 주식회사 Anti-obesity Agents Comprising Carvacrol as an Active Ingredient
JP2010138155A (en) * 2008-12-15 2010-06-24 Pola Chem Ind Inc External preparation for skin suitable for ameliorating drabness
KR101050429B1 (en) * 2009-03-18 2011-07-19 연세대학교 산학협력단 Composition for the prevention or treatment of obesity, dyslipidemia, fatty liver or insulin resistance syndrome comprising camphor as an active ingredient
KR101148623B1 (en) * 2010-03-25 2012-05-21 대구한의대학교산학협력단 A COMPOSITION COMPRISING α-THUJONE FOR PREVENTING AND TREATING COGNITIVE DYSFUNCTION AND IMPROVING MEMORY
CA2853974C (en) 2010-10-30 2020-11-10 Kindex Therapeutics, Llc Cis 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods
JP2013184942A (en) * 2012-03-09 2013-09-19 Kose Corp Antioxidant and dna damage inhibitor
KR101936688B1 (en) 2012-04-17 2019-04-09 (주)아모레퍼시픽 Whitening composition containing trolox
CN111529535A (en) 2012-09-27 2020-08-14 儿童医学中心公司 Compounds for the treatment of obesity and methods of use thereof
JP6163084B2 (en) * 2013-11-11 2017-07-12 キリン株式会社 Composition for preventing, treating and / or improving cognitive function of dementia, and medicine and food using the same
CN107073016A (en) * 2014-03-26 2017-08-18 儿童医学中心公司 Celastrol and derivative for treating obesity
RU2549475C1 (en) * 2014-05-12 2015-04-27 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Pharmaceutical composition possessing therapeutic action on various skin pathologies
JP6242746B2 (en) * 2014-05-26 2017-12-06 キリン株式会社 Medicines, foods, and compositions that improve memory learning function
US9125912B1 (en) * 2015-02-10 2015-09-08 King Saud University Method of treating ulcerative colitis
KR102043893B1 (en) * 2018-01-05 2019-11-12 인제대학교 산학협력단 Composition Comprising alpha-Humulene for Preventing or Treating Diseases Associated with Mucous Membrane of Digestive System
JP2020028263A (en) * 2018-08-23 2020-02-27 国立大学法人徳島大学 Disuse muscular atrophy suppressing agent and food composition for disuse muscular atrophy suppression
CN110141572B (en) * 2019-06-20 2020-05-12 牡丹江医学院 Medicine for treating asthma and preparation method thereof
CN112043713B (en) * 2020-09-14 2021-10-12 南通大学 Application of betulinic acid derivative in preparing medicine for treating nerve injury diseases
CN112625042B (en) * 2020-12-28 2022-04-01 北京燕化集联光电技术有限公司 Organic electroluminescent material and application thereof
CN113350360A (en) * 2021-06-18 2021-09-07 西南医科大学 Novel application of triterpenic acid compound as A beta fiber formation inhibitor drug

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5370863A (en) * 1992-12-16 1994-12-06 Miller Brewing Company Oral care compositions containing hop acids and method
US5523489A (en) * 1995-02-07 1996-06-04 Miller Brewing Company Preparation of tetrahydroisohumulones
US6129907A (en) * 1999-08-04 2000-10-10 Colgate Palmolive Company Stable hydrogenated lupulone antibacterial oral compositions
US20020086070A1 (en) * 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1901277U (en) 1964-05-25 1964-09-24 Kuhlmann Geb DEVICE FOR MAKING PERFORMANCE IN PROFILE BARS.
US3933919A (en) 1964-12-15 1976-01-20 Geoffrey Wilkinson Hydroformylation of mono-α-olefins and mono-α-acetylenes
US3451821A (en) 1965-03-01 1969-06-24 Kalamazoo Spice Extract Co Increasing the utilization of hops and improving flavor control of malt beverages and the like
GB1140545A (en) 1965-03-01 1969-01-22 Kalamazoo Spice Extract Co Hop flavours for malt beverages and the like
US3720517A (en) 1970-12-21 1973-03-13 Hamm T Brewing Co Preparation of a fermented malt champagne
US3932603A (en) 1971-05-28 1976-01-13 General Foods Corporation Oral preparations for reducing the incidence of dental caries
GB1372932A (en) 1971-03-15 1974-11-06 Gen Foods Corp Anti-caries compositions
US3965188A (en) 1972-01-10 1976-06-22 Miller Brewing Company Hop extract process and product
CH617326A5 (en) 1975-12-04 1980-05-30 Siegfried Ag
US4170638A (en) 1976-11-05 1979-10-09 S. S. Steiner, Inc. Method for producing a deodorant
US4148873A (en) 1976-11-05 1979-04-10 S. S. Steiner, Inc. Method for treating the skin with extracts of hops
US4123561A (en) 1977-02-01 1978-10-31 S.S. Steiner, Inc. Method for processing hops for brewing
US4401684A (en) 1981-10-01 1983-08-30 Australian Hop Marketers Pty. Ltd. Preservation of hops utilizing ascorbic acid
US4389421A (en) 1981-10-30 1983-06-21 Busch Industrial Products Corporation Method for controlling light stability in malt beverages and product thereof
BE896610A (en) 1982-05-06 1983-08-16 Hop Developments Ltd EXTRACTION OF PLANT MATERIAL USING CARBONIC ANHYDRIDE
US4486436A (en) 1982-07-22 1984-12-04 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US4473551A (en) 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
US4644084A (en) 1984-01-25 1987-02-17 Miller Brewing Company Preparation of tetrahydroisohumulones
GB2187755B (en) 1984-02-28 1990-03-28 Kalamazoo Holdings Inc Separation of the constituents of co2 hop extracts
SU1247011A1 (en) 1985-02-20 1986-07-30 Специальное Конструкторское Бюро Химизации Научно-Производственного Объединения "Аэрозоль" Agent for hair care
DE3513169A1 (en) 1985-04-12 1986-10-16 Hopstabil Hopfenverarbeitungs-Gesellschaft mbH, 8069 Wolnzach METHOD FOR PRODUCING ISOHUMULONES
US4767640A (en) 1985-10-29 1988-08-30 Miller Brewing Company Light stable hop extracts and method of preparation
US4692280A (en) 1986-12-01 1987-09-08 The United States Of America As Represented By The Secretary Of Commerce Purification of fish oils
US5041300A (en) 1987-04-03 1991-08-20 Kalamazoo Holdings, Inc. Hop flavor which is odor forming impurity free
DE3712986A1 (en) 1987-04-16 1988-10-27 Marbert Gmbh MEDICAL PREPARATIONS BASED ON TREASURE EXTRACT, METHOD FOR THE PRODUCTION THEREOF AND USE OF TREATMENT EXTRACT FOR THE PRODUCTION OF COSMETIC PREPARATIONS AND A SPECIAL TREATMENT EXTRACT
US4857554A (en) 1987-08-17 1989-08-15 Georgios Kallimanis Method for the treatment of psoriasis
US5166449A (en) 1988-08-15 1992-11-24 Kalamazoo Holdings, Inc. Synthesis of hexahydrolupulone, novel forms thereof, and its use as a selective inhibitor of cell growth and multiplication
US5082975A (en) 1988-08-15 1992-01-21 Kalamazoo Holdings, Inc. Synthesis of hexahydrolupulone, novel forms thereof, and its use as a selective inhibitor of cell growth and multiplication
DE3931147A1 (en) 1989-09-19 1991-03-28 Solong Natural Ltd New nerve tonic contg. extract of avena sativa - used to treat frigidity and increase libido in women
US5013571A (en) 1990-01-31 1991-05-07 Pfizer Inc. Methods for making tetrahydroisoalpha and hexahydroisoalpha acids
EP0474892B1 (en) 1990-09-10 1996-04-10 Fromm, Mayer-Bass Limited Process for the isomerisation of humulone in a carbon dioxide-hop extract and method for extracting the isohumulone
JP3155003B2 (en) 1990-11-06 2001-04-09 サントリー株式会社 Method for producing hop extract and hop extract obtained by the method
TW199905B (en) 1992-02-03 1993-02-11 J E Siebel Sons Company Inc Method and composition for enhancing foam properties of fermented malt beverages
RU2045955C1 (en) 1992-02-24 1995-10-20 Никитина Татьяна Ивановна Method for treating adnexites
WO1994003192A1 (en) 1992-07-29 1994-02-17 Drymed A/S Composition comprising fertilized shell eggs
US5286506A (en) 1992-10-29 1994-02-15 Bio-Technical Resources Inhibition of food pathogens by hop acids
US5296637A (en) 1992-12-31 1994-03-22 Kalamazoo Holdings, Inc. Production of odor-free tetrahydroisohumulates from alpha acids via their tetrahydrohumulates and subsequent isomerization
US5866162A (en) 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
JP2677762B2 (en) * 1994-04-08 1997-11-17 株式会社神戸製鋼所 Oil-cooled compressor
EP0677289B1 (en) 1994-04-12 1999-01-13 Hoechst Marion Roussel, Ltd. Pharmaceutical composition for treating osteoporosis
AT404469B (en) 1994-05-06 1998-11-25 Tulln Zuckerforschung Gmbh METHOD FOR THE PRESERVATION OF SUGAR-BASED PLANT EXTRACTS OR. JUICES
IN184685B (en) 1996-02-14 2000-09-23 Nat Inst Immunology
US5827895A (en) 1996-02-27 1998-10-27 Regents Of The University Of Minnesota Hexahydrolupulones useful as anticancer agents
US6020019A (en) 1996-03-26 2000-02-01 Miller Brewing Company Hydrogenation of hop soft resins using CO2
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US5968539A (en) 1997-06-04 1999-10-19 Procter & Gamble Company Mild, rinse-off antimicrobial liquid cleansing compositions which provide residual benefit versus gram negative bacteria
MY120052A (en) 1997-09-17 2005-08-30 Honda Motor Co Ltd Lock-up control device
US6251461B1 (en) 1997-10-10 2001-06-26 S. S. Steiner, Inc. Antimicrobial activity of hops extract against Clostridium botulinum, Clostridium difficile and Helicobacter pylori
CA2321737A1 (en) 1998-03-04 1999-09-10 Nps Pharmaceuticals, Inc. Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid
US6224871B1 (en) 1998-03-11 2001-05-01 Reliv International, Inc. Dietary supplement for nutritionally promoting healthy joint function
US5919813C1 (en) 1998-03-13 2002-01-29 Univ Johns Hopkins Med Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy
JPH11335231A (en) * 1998-05-20 1999-12-07 Shiseido Co Ltd Skin lotion for slimming body
WO1999061038A1 (en) * 1998-05-29 1999-12-02 Adams Food Ltd. Composition having therapeutic and/or nutritionally active substituent
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
GB2336363B (en) * 1998-08-13 2000-03-15 English Hop Products Limited Hydrogenation of hop acids
DE19841615A1 (en) 1998-09-11 2000-03-16 Fritz Armin Mueller Medicinal wine for alleviating pain and other symptoms of premenstrual syndrome, comprising mixture of extracts of different plants in dry white wine
ES2147538B1 (en) 1999-01-29 2001-04-01 Revlon Consumer Prod Corp A CAPILLARY LOTION WITH IMPROVED PROPERTIES IN ITS HAIR PROTECTIVE AND PREVENTIVE ACTION OF HIS FALL, AND REDUCTION OF THE EXTERNAL EFFECTS OF ANDROGENETIC ALOPECIA AND WITH THAT OF THE HAIR FALL.
ZA200000857B (en) 1999-02-11 2001-05-31 Marx Anna Susan Pharmaceutical composition.
US6801860B1 (en) 1999-02-15 2004-10-05 Genetics Institute, Llc Crystal structure of cPLA2 and methods of identifying agonists and antagonists using same
US6383527B1 (en) 1999-03-04 2002-05-07 Nps Pharmaceuticals, Inc. Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
US6210701B1 (en) 1999-04-30 2001-04-03 Healthcomm International, Inc. Medical food for treating inflammation-related diseases
JP4173606B2 (en) 1999-06-18 2008-10-29 サントリー株式会社 Method for producing low acid beverage
WO2001021165A1 (en) 1999-09-21 2001-03-29 Rutgers, The State University Resveratrol analogs for prevention of disease
US6264995B1 (en) 1999-10-19 2001-07-24 Thomas Newmark Herbal composition for reducing inflammation and methods of using same
JP2001161338A (en) 1999-12-09 2001-06-19 Kyodo Shoji:Kk Method for producing sparkling liquor
US6200594B1 (en) 1999-12-29 2001-03-13 Vital Dynamics, Inc. Breast-enhancing, herbal compositions and methods of using same
US6953593B2 (en) 2000-02-01 2005-10-11 Lipoprotein Technologies, Inc. Sustained-release microencapsulated delivery system
US6583322B1 (en) 2000-02-25 2003-06-24 Kalamazoo Holdings, Inc. Dihydro and hexahydro isoalpha acids having a high ratio of trans to cis isomers, production thereof, and products containing the same
KR20030005252A (en) 2000-03-31 2003-01-17 니신 오일 밀스 가부시키가이샤 External preparation for the skin and beautifying agents
US6440465B1 (en) 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
US6492429B1 (en) 2000-07-10 2002-12-10 N.V. Nutricia Composition for the treatment of osteoarthritis
US6908630B2 (en) 2000-08-01 2005-06-21 Metaproteomics, Llc Combinations of sesquiterpene lactones and ditepene triepoxide lactones for synergistic inhibition of cyclooxygenase-2
US20020076452A1 (en) 2000-08-01 2002-06-20 Ashni Naturaceuticals, Inc. Combinations of sesquiterpene lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
US6629835B2 (en) * 2000-08-01 2003-10-07 Metaproteomics, Llc Combinations of diterpene triepoxide lactones and ditepene lactones or triterpenes for synergistic inhibition of cyclooxygenase-2
FR2815227B1 (en) 2000-10-17 2003-04-11 Schwartz Laboratoires Robert ANTI-STRESS COMPOSITION FOR PRIMARY INCORPORATION IN NUTRITIONAL VEHICLES
US6790459B1 (en) 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
JP2002302441A (en) * 2001-02-02 2002-10-18 Nisshin Oil Mills Ltd:The Composition and food and drink for obtunding symptom of premenstrual syndrome
US20030035851A1 (en) 2001-02-08 2003-02-20 Sophie Chen Anti-cancer agents and method of use thereof
US6391346B1 (en) * 2001-04-05 2002-05-21 Thomas Newmark Anti-inflammatory, sleep-promoting herbal composition and method of use
US20030003212A1 (en) 2001-06-13 2003-01-02 Givaudan Sa Taste modifiers
US20040115290A1 (en) 2001-06-20 2004-06-17 Tripp Matthew L. Modulation of inflammation by hops fractions and derivatives
US20040219240A1 (en) 2001-06-20 2004-11-04 Babish John G. Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
US7718198B2 (en) 2001-06-20 2010-05-18 Metaproteomics, Llc Treatment modalities for autoimmune diseases
US8168234B2 (en) 2001-06-20 2012-05-01 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
US7901714B2 (en) 2001-06-20 2011-03-08 Metaproteomics, Llp Treatment modalities for autoimmune diseases
US8142819B2 (en) 2002-10-21 2012-03-27 Metaproteomics, Llc Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response
US7901713B2 (en) 2001-06-20 2011-03-08 Metaproteomics, Llc Inhibition of COX-2 and/or 5-LOX activity by fractions isolated or derived from hops
US7205151B2 (en) 2001-06-20 2007-04-17 Metaproteomics, Llc Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
US7270835B2 (en) 2001-06-20 2007-09-18 Metaproteomics, Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response
EP1446136B1 (en) 2001-10-26 2010-09-29 Metaproteomics, LLC Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US7279185B2 (en) 2001-10-26 2007-10-09 Metaproteonics, Llc Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2
US20060233902A1 (en) 2002-02-14 2006-10-19 Kirin Beer Kabushiki Kaisha Compositions and foods for improving lipid metabolism
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US20030228369A1 (en) 2002-05-06 2003-12-11 Kuhrts Eric Hauser Process for conversion of high viscosity fluids and compositions thereof
MXPA05004288A (en) 2002-10-21 2005-08-02 Metaproteomics Llc Compositions that treat or inhibit pathological conditions associated with inflammatory response.
US7144590B2 (en) 2003-01-09 2006-12-05 Lipoprotein Technologies, Inc. Bioactive compositions derived from humulus lupulus
EP1543834A1 (en) 2003-12-16 2005-06-22 Biodynamics Production of hop extracts having oestrogenic and antiproliferative bioactivity
US20050192356A1 (en) 2004-02-27 2005-09-01 Babish John G. Synergistic anti-inflammatory pharmaceutical compositions and methods of use
US7914831B2 (en) 2004-02-27 2011-03-29 Metaproteomics, Llc Synergistic anti-inflammatory pharmaceutical compositions and related methods using curcuminoids or methylxanthines
US20080248131A1 (en) 2005-08-09 2008-10-09 Metaproteomics, Llc Protein Kinase Modulation by Hops and Acacia Products
US8062898B2 (en) 2006-10-20 2011-11-22 The Board Of Trustees Of The University Of Illinois Selection and rational development of solvent systems in counter-current chromatograph
FR2910325B1 (en) 2006-12-22 2010-03-19 Kronenbourg Brasseries USE OF LUPULONES FOR THE PREVENTION AND THERAPY OF COLORECTAL CANCER.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5370863A (en) * 1992-12-16 1994-12-06 Miller Brewing Company Oral care compositions containing hop acids and method
US5523489A (en) * 1995-02-07 1996-06-04 Miller Brewing Company Preparation of tetrahydroisohumulones
US6129907A (en) * 1999-08-04 2000-10-10 Colgate Palmolive Company Stable hydrogenated lupulone antibacterial oral compositions
US20020086070A1 (en) * 2000-03-11 2002-07-04 Kuhrts Eric Hauser Anti-inflammatory and connective tissue repair formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1558271A2 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846115B2 (en) 2001-11-13 2014-09-30 Metaproteomics, Inc. Anti-inflammatory cyclooxygenase inhibitors
US8241674B2 (en) 2007-05-11 2012-08-14 Metaproteomics, Llc Methods and compositions for heavy metal detoxification
CN112794872B (en) * 2021-04-02 2022-07-15 湖南德诺贝莱健康产业有限公司 Method for extracting luteolin-3' -glucuronide from rosemary

Also Published As

Publication number Publication date
WO2004037180A2 (en) 2004-05-06
JP2006508182A (en) 2006-03-09
AU2003286549A1 (en) 2004-05-13
AU2003286549B2 (en) 2006-11-30
US8486457B2 (en) 2013-07-16
AU2003286549C1 (en) 2004-05-13
CA2503196C (en) 2011-08-02
NZ539642A (en) 2007-01-26
KR20050071605A (en) 2005-07-07
CA2503196A1 (en) 2004-05-06
US20070160692A1 (en) 2007-07-12
EP1558271A4 (en) 2006-01-11
MXPA05004288A (en) 2005-08-02
EP1558271A2 (en) 2005-08-03

Similar Documents

Publication Publication Date Title
WO2004037180A3 (en) Compositions that treat or inhibit pathological conditions associated with inflammatory response
Lin et al. A review of antioxidant and pharmacological properties of phenolic compounds in Acacia confusa
BR0116345A (en) Smelly Counteracting Compositions
BRPI0606328B8 (en) use of a phenylpropanoid glycoside from an ajuga reptans plant, use of a whole cell homogenate of ajuga reptans, use of a purified extract of ajuga reptans and use of phenylpropanoids from an ajuga reptans plant
Rhyu et al. Characterization of alkyl thiosulfinate in Allium hookeri root using HPLC-ESI-MS
WO2008065316A3 (en) Ointment compositions comprising a vitamin d derivative
DE60135021D1 (en) PEST CONTROL CONNECTIONS
BR0113104A (en) Oil / fat composition
RS50035B (en) PHARMACEUTICAL COMPOSITION CONTAINING PHENOFIBRATE AND PROCEDURE FOR ITS PRODUCTION
Subapriya et al. Expression of PCNA, cytokeratin, Bcl-2 and p53 during chemoprevention of hamster buccal pouch carcinogenesis by ethanolic neem (Azadirachta indica) leaf extract
DE60232005D1 (en) STABILIZED AZITHROMYCIN COMPOSITIONS
Nam et al. Antioxidant activities and phenolic compounds of several tissues of pawpaw (Asimina triloba [L.] Dunal) grown in Korea
AR017662A1 (en) ANTITRANSPIRING OR DEODORANT COMPOSITIONS
Alberto et al. Inhibition of cyclooxygenase activity by standardized hydroalcoholic extracts of four Asteraceae species from the Argentine Puna
PT1178778E (en) GRANULES CONTAINING A VEGETABLE SUBSTANCE AND THEIR PREPARATION PROCEDURE
ATE342726T1 (en) PLANT EXTRACT MIXTURES (CISSUS, VERNONIA, BRILLANTAISIA) AND THEIR USES
WO2005051083A3 (en) Molluscicidal and anti-barnacle compounds
Olennikov et al. Phytoecdysteroids from Silene jenisseensis
Hsieh et al. Effects of Chamaecyparis formosensis Matasumura extractives on lipopolysaccharide-induced release of nitric oxide
NO20080515L (en) Active fraction from a polar solvent extract of lates from the euphoribiaceae plants
Olennikov Phytoecdysteroids and flavonoids from Gastrolychnis tristis
Abu-gabal et al. Phytophenolics composition, hypolipidemic, hypoglycemic and antioxidative effects of the leaves of Fortunella japonica (Thunb.) swingle
ES2190916T3 (en) ALPHA KETA, BETA, NOT SATURATED.
BR0011261A (en) Oral composition comprising perlite, and use of perlite
BRPI0811372A2 (en) "READY-TO-EAT FOOD USE, METHOD AND COMPOSITION"

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005501640

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/004288

Country of ref document: MX

Ref document number: 2503196

Country of ref document: CA

Ref document number: 1020057006910

Country of ref document: KR

Ref document number: 2003286549

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 539642

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003777751

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 1020057006910

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003777751

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007160692

Country of ref document: US

Ref document number: 10532388

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10532388

Country of ref document: US